Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Exclusion Criteria16

• Diagnosed with any other cancer within the past 5 years;
• Known allergy to any component of the drug;
• Congenital or acquired immune deficiency (such as HIV infection);
• The presence of any active, known or suspected autoimmune disease (such as, but not limited to, interstitial pneumonia, uveitis, enteritis, hepatitis, arthritis, nephritis, hypophysitis, hyperthyroidism, hypothyroidism, etc.); Medical history of vitiligo; asthma which requires bronchodilators for medical intervention;
• Active infection requiring systemic treatment;
• Previously treatment with PD-1 and/or PD-L1, or CTLA-4 antibody, or other medications targeting immunomodulatory receptors;
• Patients with grade\>2 unrelieved toxic reactions (based on National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] version 5.0) caused by any previous treatment;
• With a history of myocardial infarction,stroke, unstable angina, decompensated heart failure, or deep vein thrombosis;
• Long-term uncured wounds or fractures; Major surgery or severe traumatic injury, fracture or ulcer within 4 weeks;
• Pregnant or lactating women;
• With metastatic diseases;
• Liver/renal insufficiency;
• Those who have a history of psychotropic drug abuse and cannot get rid of it or those with mental disorders;
• Those who have participated in clinical trials with other drugs within 4 weeks;
• Patients with concomitant diseases or abnormal test results which interfere with the ability to receive anticancer therapy judged by the investigator;
• Patients could not gain the maximum benefit from this study judged by the investigator.